280 related articles for article (PubMed ID: 9399601)
1. Mycophenolate mofetil.
Sievers TM; Rossi SJ; Ghobrial RM; Arriola E; Nishimura P; Kawano M; Holt CD
Pharmacotherapy; 1997; 17(6):1178-97. PubMed ID: 9399601
[TBL] [Abstract][Full Text] [Related]
2. Mycophenolate mofetil. A review of its pharmacodynamic and pharmacokinetic properties and clinical efficacy in renal transplantation.
Fulton B; Markham A
Drugs; 1996 Feb; 51(2):278-98. PubMed ID: 8808168
[TBL] [Abstract][Full Text] [Related]
3. [Use of mycophenolate mofetil in kidney transplantation].
Hrvacevic R; Ignjatovic Lj; Vavic N
Vojnosanit Pregl; 2001; 58(4):415-9. PubMed ID: 11712223
[TBL] [Abstract][Full Text] [Related]
4. Mycophenolate mofetil: effects on clinical transplantation.
Holt CD; Sievers TM; Ghobrial RM; Rossi SJ; Goss JA; McDiarmid SV
BioDrugs; 1998 Nov; 10(5):373-84. PubMed ID: 18020609
[TBL] [Abstract][Full Text] [Related]
5. [Mycophenolate mofetil, a possible new immunosuppresant].
Weberová J; Voboril R; Semecký V
Ceska Slov Farm; 2002 Sep; 51(5):220-5. PubMed ID: 12407919
[TBL] [Abstract][Full Text] [Related]
6. Mycophenolate mofetil in kidney transplantation.
Lui SL; Halloran PF
Curr Opin Nephrol Hypertens; 1996 Nov; 5(6):508-13. PubMed ID: 8978998
[TBL] [Abstract][Full Text] [Related]
7. Mycophenolate mofetil in cardiac transplantation.
Kobashigawa JA
Curr Opin Cardiol; 1998 Mar; 13(2):117-21. PubMed ID: 9593551
[TBL] [Abstract][Full Text] [Related]
8. Mycophenolate mofetil: An update.
Villarroel MC; Hidalgo M; Jimeno A
Drugs Today (Barc); 2009 Jul; 45(7):521-32. PubMed ID: 19834629
[TBL] [Abstract][Full Text] [Related]
9. Individualization of mycophenolate mofetil dose in renal transplant recipients.
van Hest RM; Hesselink DA; Vulto AG; Mathot RA; van Gelder T
Expert Opin Pharmacother; 2006 Mar; 7(4):361-76. PubMed ID: 16503809
[TBL] [Abstract][Full Text] [Related]
10. Preliminary risk-benefit assessment of mycophenolate mofetil in transplant rejection.
Simmons WD; Rayhill SC; Sollinger HW
Drug Saf; 1997 Aug; 17(2):75-92. PubMed ID: 9285199
[TBL] [Abstract][Full Text] [Related]
11. Mycophenolate mofetil: suggested guidelines for use in kidney transplantation.
Behrend M
BioDrugs; 2001; 15(1):37-53. PubMed ID: 11437674
[TBL] [Abstract][Full Text] [Related]
12. Induction of inosine monophosphate dehydrogenase activity after long-term treatment with mycophenolate mofetil.
Sanquer S; Breil M; Baron C; Dhamane D; Astier A; Lang P
Clin Pharmacol Ther; 1999 Jun; 65(6):640-8. PubMed ID: 10391669
[TBL] [Abstract][Full Text] [Related]
13. [Pharmacological profiles of mycophenolate mofetil (CellCept), a new immunosuppressive agent].
Yashima Y; Ohgane T
Nihon Yakurigaku Zasshi; 2001 Feb; 117(2):131-7. PubMed ID: 11233304
[TBL] [Abstract][Full Text] [Related]
14. Enteric-coated mycophenolate sodium: a review of its use in the prevention of renal transplant rejection.
Sanford M; Keating GM
Drugs; 2008; 68(17):2505-33. PubMed ID: 19016576
[TBL] [Abstract][Full Text] [Related]
15. Effect of mycophenolate mofetil therapy on inosine monophosphate dehydrogenase induction in red blood cells of heart transplant recipients.
Weigel G; Griesmacher A; Zuckermann AO; Laufer G; Mueller MM
Clin Pharmacol Ther; 2001 Mar; 69(3):137-44. PubMed ID: 11240978
[TBL] [Abstract][Full Text] [Related]
16. A review of clinical experience with the novel immunosuppressive drug mycophenolate mofetil in renal transplantation.
Behrend M
Clin Nephrol; 1996 May; 45(5):336-41. PubMed ID: 8738667
[TBL] [Abstract][Full Text] [Related]
17. The pharmacokinetic-pharmacodynamic relationship for mycophenolate mofetil in renal transplantation.
Hale MD; Nicholls AJ; Bullingham RE; Hené R; Hoitsma A; Squifflet JP; Weimar W; Vanrenterghem Y; Van de Woude FJ; Verpooten GA
Clin Pharmacol Ther; 1998 Dec; 64(6):672-83. PubMed ID: 9871432
[TBL] [Abstract][Full Text] [Related]
18. Mycophenolate mofetil: a unique immunosuppressive agent.
Hood KA; Zarembski DG
Am J Health Syst Pharm; 1997 Feb; 54(3):285-94. PubMed ID: 9028422
[TBL] [Abstract][Full Text] [Related]
19. Pharmacokinetics and pharmacodynamics of mycophenolic acid after enteric-coated mycophenolate versus mycophenolate mofetil in patients with progressive IgA nephritis.
Czock D; Rasche FM; Carius A; Glander P; Budde K; Bauer S; Keller F; von Müller L
J Clin Pharmacol; 2007 Jul; 47(7):850-9. PubMed ID: 17526858
[TBL] [Abstract][Full Text] [Related]
20. Purine metabolism and immunosuppressive effects of mycophenolate mofetil (MMF).
Allison AC; Eugui EM
Clin Transplant; 1996 Feb; 10(1 Pt 2):77-84. PubMed ID: 8680053
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
